For financial professionals in the UK

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA | Janus Henderson Investors

Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Daniel started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors.

Daniel received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a PhD from Stanford University’s programme in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 21 years of financial industry experience.

Products Managed

Articles Written

Understanding the impact of delta

Understanding the impact of delta

In the latest video from our ongoing COVID-19 series, Portfolio Manager Dan Lyons and Research Analyst Agustin Mohedas explain why, as well as how the effort to end the pandemic is impacting biopharma.

Vaccines prove their worth for global health care

Vaccines prove their worth for global health care

In places where vaccination rates are rising, COVID-19 cases are dropping dramatically. What that means for ending the pandemic and health care long term.

COVID variants: The impact on pandemic trajectory & biopharma stocks

COVID variants: The impact on pandemic trajectory & biopharma stocks

Making sense of the latest developments around COVID-19 variants and what investors should consider now.

COVID-19 vaccine beats expectations

COVID-19 vaccine beats expectations

How a novel vaccine candidate from Pfizer and BioNTech could shape the trajectory of the global pandemic.

What a return to ‘normal’ could mean for equities

What a return to ‘normal’ could mean for equities

In our ongoing video series on COVID-19, a discussion of the pandemic’s trajectory, vaccine development and investment considerations post-crisis.

Podcast: Understanding the science and investment implications of COVID-19 (part 7)

Podcast: Understanding the science and investment implications of COVID-19 (part 7)

In our ongoing series on COVID-19, Portfolio Manager and Research Analyst Dan Lyons and Director of Research Matt Peron discuss the current state of the pandemic and what investors should consider as the economy tries to return to “normal.”

COVID-19: Understanding the science & investment implications (Part 4)

COVID-19: Understanding the science & investment implications (Part 4)

A new video series from our health care team offers unique insight into the scientific and investment implications of the COVID-19 crisis.

Podcast: Understanding the science and investment implications of COVID-19 (part 4)

Podcast: Understanding the science and investment implications of COVID-19 (part 4)

In this fourth installment of a series on the scientific and investment implications of COVID-19, Portfolio Manager and Research Analyst Dan Lyons explains the latest drug developments, as well as whether the US can meet its aggressive testing goals to reopen the economy.

Under the microscope: disruption in healthcare

Under the microscope: disruption in healthcare

Disease treatment is changing rapidly, leading to new therapies and better long-term results for patients. Portfolio Manager Andy Acker and Research Analyst Dan Lyons discuss how these exciting advances are leading to new investment opportunities in healthcare.

Biotech: focusing on fundamentals
Investment Viewpoints

Biotech: focusing on fundamentals

Portfolio managers, Andy Acker and Dan Lyons, and research analyst, John Scotti, explain why fundamentals matter when investing in biotech’s innovation boom.